CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial
Authors
P. Zhang
Ruihong Dai (ORCID: https://orcid.org/0009-0001-5439-8718)
CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial
P. Zhang, Ruihong Dai, Meng Cheng, Jitao Zhou et al.
Journal
BMJ Open
Topics
Biosimilars and Bioanalytical Methods
article
CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial
P. Zhang, Ruihong Dai, Meng Cheng, Jitao Zhou, Ming Liu, Feng Bi
article en
Abstract
No abstract available for this paper.
Publication Tag
BMJ OpenVol. 16(1)
Institutions
Sichuan University (CN), West China Hospital of Sichuan University (CN), Sichuan Cancer Hospital (CN)
Funders
Sichuan University, West China Hospital, Sichuan University